BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Polee MB, Hop WC, Kok TC, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Stoter G, van der Gaast A. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer. 2003;89:2045-2050. [PMID: 14647136 DOI: 10.1038/sj.bjc.6601364] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Nishisako S, Yamaguchi T, Hirayama M, Higa K, Aoki D, Sasaki C, Noma H, Shimazaki J. Donor-Related Risk Factors for Graft Decompensation Following Descemet's Stripping Automated Endothelial Keratoplasty. Front Med 2022;9:810536. [DOI: 10.3389/fmed.2022.810536] [Reference Citation Analysis]
2 Hussein M, Alzoubaidi D, O'Donnell M, de la Serna A, Bassett P, Varbobitis I, Hengehold T, Ortiz Fernandez-Sordo J, Rey JW, Hayee B, Despott EJ, Murino A, Graham D, Latorre M, Moreea S, Boger P, Dunn J, Mainie I, Mullady D, Early D, Ragunath K, Anderson J, Bhandari P, Goetz M, Kiesslich R, Coron E, Rodriguez de Santiago E, Gonda T, Gross SA, Lovat LB, Haidry R. Hemostatic powder TC-325 treatment of malignancy-related upper gastrointestinal bleeds: International registry outcomes. J Gastroenterol Hepatol 2021. [PMID: 34132412 DOI: 10.1111/jgh.15579] [Reference Citation Analysis]
3 Pogorzelski M, Hilser T, Ting SC, Kansy B, Gauler TC, Stuschke M, Schmid KW, Lang S, Grünwald V, Schuler M, Kasper S. Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab. Front Oncol 2021;11:635096. [PMID: 34055606 DOI: 10.3389/fonc.2021.635096] [Reference Citation Analysis]
4 Shrestha R, Tripathi R, Goyal P, Agarwal C, Gupta M, Mehta A, Doval DC. Long-Term Survival in an Esophageal Cancer Patient with Multiple Recurrences. J Gastrointest Cancer 2020;51:695-7. [PMID: 31989443 DOI: 10.1007/s12029-020-00366-3] [Reference Citation Analysis]
5 Li B, Wang R, Zhang T, Sun X, Jiang C, Li W, Zou B, Xie P, Meng X, Sun X, Wang L, Yu J. Development and validation of a nomogram prognostic model for esophageal cancer patients with oligometastases. Sci Rep 2020;10:11259. [PMID: 32647289 DOI: 10.1038/s41598-020-68160-6] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Tian YM, Huang WZ, Lan YH, Zhao C, Bai L, Han F. Prognostic model and optimal treatment for patients with stage IVc nasopharyngeal carcinoma at diagnosis. Sci Rep 2019;9:19272. [PMID: 31848409 DOI: 10.1038/s41598-019-55586-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
7 Kim EJ, Kim JH, Song HJ, Park SR, Kim YH, Kim HR, Kim SB. Impact of sequential lines of palliative chemotherapy in patients with recurrent/metastatic esophageal squamous cell carcinoma: A retrospective analysis of 107 patients at a single center. Asia Pac J Clin Oncol 2020;16:e53-62. [PMID: 31657877 DOI: 10.1111/ajco.13283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 de Man FM, van Eerden RAG, Oomen-de Hoop E, Veraart JN, van Doorn N, van Doorn L, van der Gaast A, Mathijssen RHJ. Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients. Cancers (Basel) 2019;11:E826. [PMID: 31200588 DOI: 10.3390/cancers11060826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
9 Sharma M, Radhakrishnan R. Revisiting and revising the definition of oral submucous fibrosis. Oral Oncol 2019;92:94. [PMID: 30853277 DOI: 10.1016/j.oraloncology.2019.03.004] [Reference Citation Analysis]
10 Wang T, Chen VC, Yang Y, Chen C, Lee C, Wu S. The effects of anxiety on the receipt of treatments for esophageal cancer. Psycho-Oncology 2019;28:31-8. [DOI: 10.1002/pon.4903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Vendrely V, Launay V, Najah H, Smith D, Collet D, Gronnier C. Prognostic factors in esophageal cancer treated with curative intent. Dig Liver Dis 2018;50:991-6. [PMID: 30166221 DOI: 10.1016/j.dld.2018.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
12 Yao YW, He YF, Han XH, Ji CS, Hu B. Clinical research of individualized therapy in advanced esophageal cancer based on the ERCC1 C8092A genotype. Oncol Lett 2018;16:2539-48. [PMID: 30013648 DOI: 10.3892/ol.2018.8894] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Shen S, Araujo JL, Altorki NK, Sonett JR, Rodriguez A, Sungur-Stasik K, Spinelli CF, Neugut AI, Abrams JA. Variation by stage in the effects of prediagnosis weight loss on mortality in a prospective cohort of esophageal cancer patients. Dis Esophagus 2017;30:1-7. [PMID: 28859366 DOI: 10.1093/dote/dox073] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
14 Penniment MG, De Ieso PB, Harvey JA, Stephens S, Au HJ, O'Callaghan CJ, Kneebone A, Ngan SY, Ward IG, Roy R, Smith JG, Nijjar T, Biagi JJ, Mulroy LA, Wong R; TROG 03.01/CCTG ES.2 group. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). Lancet Gastroenterol Hepatol 2018;3:114-24. [PMID: 29248399 DOI: 10.1016/S2468-1253(17)30363-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 6.2] [Reference Citation Analysis]
15 Opstelten JL, de Wijkerslooth LR, Leenders M, Bac DJ, Brink MA, Loffeld BC, Meijnen-Bult MJ, Minderhoud IM, Verhagen MA, van Oijen MG, Siersema PD. Variation in palliative care of esophageal cancer in clinical practice: factors associated with treatment decisions. Dis Esophagus. 2017;30:1-7. [PMID: 26919349 DOI: 10.1111/dote.12478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
16 Davidson M, Chau I, Cunningham D, Khabra K, Iveson T, Hickish T, Seymour M, Starling N. Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. World J Gastrointest Oncol 2017; 9(8): 333-340 [PMID: 28868114 DOI: 10.4251/wjgo.v9.i8.333] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
17 Wang J, Suri JS, Allen PK, Liao Z, Komaki R, Ho L, Hofstetter WL, Lin SH. Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer. Am J Clin Oncol 2016;39:228-35. [PMID: 24710122 DOI: 10.1097/COC.0000000000000066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
18 Park SY, Yoon JK, Lee SJ, Haam S, Jung J. Postoperative change of the psoas muscle area as a predictor of survival in surgically treated esophageal cancer patients. J Thorac Dis 2017;9:355-61. [PMID: 28275484 DOI: 10.21037/jtd.2017.02.42] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
19 Ma L, Luo GY, Ren YF, Qiu B, Yang H, Xie CX, Liu SR, Liu SL, Chen ZL, Li Q, Fu JH, Liu MZ, Hu YH, Ye WF, Liu H. Concurrent chemoradiotherapy combined with enteral nutrition support: a radical treatment strategy for esophageal squamous cell carcinoma patients with malignant fistulae. Chin J Cancer. 2017;36:8. [PMID: 28077159 DOI: 10.1186/s40880-016-0171-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
20 Verma A, Phua CK, Wu QM, Sim WY, Rui AW, Goh SK, Ho B, Kor AC, Wong AS, Lim AY, Tai DY, Abisheganaden J. Our Clinical Experience of Self-Expanding Metal Stent for Malignant Central Airway Obstruction. J Clin Med Res 2017;9:58-63. [PMID: 27924176 DOI: 10.14740/jocmr2811w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
21 Sigounas DE, Krystallis C, Couper G, Paterson-Brown S, Tatsioni A, Plevris JN. Argon plasma coagulation compared with stent placement in the palliative treatment of inoperable oesophageal cancer. United European Gastroenterol J 2017;5:21-31. [PMID: 28405318 DOI: 10.1177/2050640616650786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
22 Shapiro J, van Klaveren D, Lagarde SM, Toxopeus ELA, van der Gaast A, Hulshof MCCM, Wijnhoven BPL, van Berge Henegouwen MI, Steyerberg EW, van Lanschot JJB. Prediction of survival in patients with oesophageal or junctional cancer receiving neoadjuvant chemoradiotherapy and surgery. British Journal of Surgery 2016;103:1039-47. [DOI: 10.1002/bjs.10142] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
23 Kim HS, Kim JH, Kim JW, Kim BC. Chemotherapy in Elderly Patients with Gastric Cancer. J Cancer 2016;7:88-94. [PMID: 26722364 DOI: 10.7150/jca.13248] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
24 Wulaningsih W, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N, Walldius G, Jungner I, Ng T, Van Hemelrijck M. Serum lactate dehydrogenase and survival following cancer diagnosis. Br J Cancer 2015;113:1389-96. [PMID: 26469834 DOI: 10.1038/bjc.2015.361] [Cited by in Crossref: 36] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
25 Wei XL, Zhang DS, He MM, Jin Y, Wang DS, Zhou YX, Bai L, Li ZZ, Luo HY, Wang FH, Xu RH. The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma. Tumour Biol 2016;37:1879-87. [PMID: 26323257 DOI: 10.1007/s13277-015-3851-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
26 Zhang J, Yao YH, Li BG, Yang Q, Zhang PY, Wang HT. Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. Sci Rep 2015;5:9800. [PMID: 25902419 DOI: 10.1038/srep09800] [Cited by in Crossref: 55] [Cited by in F6Publishing: 64] [Article Influence: 7.9] [Reference Citation Analysis]
27 Fakhrian K, Ordu AD, Nieder C, Lordick F, Kup PG, Theisen J, Combs SE, Geinitz H. Outcomes of patients with squamous cell carcinoma of esophagus who did not receive surgical resection after neoadjuvant radiochemotherapy. Tumori 2015;101:263-7. [PMID: 25908044 DOI: 10.5301/tj.5000266] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Fitzgerald TL, Brinkley J, Banks S, Vohra N, Englert ZP, Zervos EE. The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review. Langenbecks Arch Surg. 2014;399:989-1000. [PMID: 25148767 DOI: 10.1007/s00423-014-1241-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
29 Yao Y, Wang H, Li B. LDH5 overexpression is associated with poor survival in patients with solid tumors: a meta-analysis. Tumor Biol 2014;35:6973-81. [DOI: 10.1007/s13277-014-1903-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
30 Jung HA, Adenis A, Lee J, Park SH, Maeng CH, Park S, Ahn HK, Shim YM, Penel N, Im YH. Nomogram to predict treatment outcome of fluoropyrimidine/platinum-based chemotherapy in metastatic esophageal squamous cell carcinoma. Cancer Res Treat 2013;45:285-94. [PMID: 24454001 DOI: 10.4143/crt.2013.45.4.285] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
31 Xu HY, DU ZD, Zhou L, Yu M, Ding ZY, Lu Y. Safety and efficacy of radiation and chemoradiation in patients over 70 years old with inoperable esophageal squamous cell carcinoma. Oncol Lett 2014;7:260-6. [PMID: 24348860 DOI: 10.3892/ol.2013.1694] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
32 Wang G, Wu A, Cheng X, Ji J. Risk factors associated with early recurrence of adenocarcinoma of gastroesophageal junction after curative resection. Chin J Cancer Res 2013;25:334-8. [PMID: 23825910 DOI: 10.3978/j.issn.1000-9604.2013.06.11] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Pan H, Cai S, Ji J, Jiang Z, Liang H, Lin F, Liu X. The Impact of Nutritional Status, Nutritional Risk, and Nutritional Treatment on Clinical Outcome of 2248 Hospitalized Cancer Patients: A Multi-Center, Prospective Cohort Study in Chinese Teaching Hospitals. Nutrition and Cancer 2013;65:62-70. [DOI: 10.1080/01635581.2013.741752] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
34 Huang J, Zhou Y, Zhang H, Qu T, Mao Y, Zhu H, Quan L, Xing P, Wang J, He J. A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Med Oncol. 2013;30:343. [PMID: 23263828 DOI: 10.1007/s12032-012-0343-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
35 Senesse P, Vasson M. Nutrition chez le patient adulte atteint de cancer : quand et comment évaluer l’état nutritionnel d’un malade atteint de cancer ? Comment faire le diagnostic de dénutrition et le diagnostic de dénutrition sévère chez un malade atteint de cancer ? Quelles sont les situations les plus à risque de dénutrition ? Nutrition Clinique et Métabolisme 2012;26:165-88. [DOI: 10.1016/j.nupar.2012.10.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
36 Carey S, Storey D, Biankin AV, Martin D, Young J, Allman-farinelli M. Long term nutritional status and quality of life following major upper gastrointestinal surgery – A cross-sectional study. Clinical Nutrition 2011;30:774-9. [DOI: 10.1016/j.clnu.2011.03.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
37 Tougeron D, Richer JP, Silvain C. Management of esophageal adenocarcinoma. J Visc Surg. 2011;148:e161-e170. [PMID: 21715236 DOI: 10.1016/j.jviscsurg.2011.05.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
38 Keld RR, Ang YS. Targeting key signalling pathways in oesophageal adenocarcinoma: A reality for personalised medicine? World J Gastroenterol 2011; 17(23): 2781-2790 [PMID: 21734785 DOI: 10.3748/wjg.v17.i23.2781] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
39 Tougeron D, Hamidou H, Scotté M, Di Fiore F, Antonietti M, Paillot B, Michel P. Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes. BMC Cancer. 2010;10:510. [PMID: 20868479 DOI: 10.1186/1471-2407-10-510] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
40 Homs MY, van der Gaast A, Siersema PD, Steyerberg EW, Kuipers EJ. WITHDRAWN: Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev 2010;:CD004063. [PMID: 20464727 DOI: 10.1002/14651858.CD004063.pub3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
41 Lord SR, Hall PS, McShane P, Brown J, Seymour MT. Factors predicting outcome for advanced gastroesophageal cancer in elderly patients receiving palliative chemotherapy. Clin Oncol (R Coll Radiol) 2010;22:107-13. [PMID: 20053542 DOI: 10.1016/j.clon.2009.12.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
42 Silver HJ, de Campos Graf Guimaraes C, Pedruzzi P, Badia M, Spuldaro de Carvalho A, Oliveira BV, Ramos GHA, Dietrich MS, Pietrobon R. Predictors of functional decline in locally advanced head and neck cancer patients from South Brazil. Head Neck 2010;32:1217-25. [DOI: 10.1002/hed.21322] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
43 Shin YK, Yoo BC, Hong YS, Chang HJ, Jung KH, Jeong SY, Park JG. Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. Electrophoresis 2009;30:2182-92. [PMID: 19582719 DOI: 10.1002/elps.200800806] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 3.9] [Reference Citation Analysis]
44 Sakaeda T, Yamamori M, Kuwahara A, Nishiguchi K. Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Adv Drug Deliv Rev 2009;61:388-401. [PMID: 19135108 DOI: 10.1016/j.addr.2008.10.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
45 Tougeron D, Di Fiore F, Thureau S, Berbera N, Iwanicki-Caron I, Hamidou H, Paillot B, Michel P. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer 2008;99:1586-92. [PMID: 19002180 DOI: 10.1038/sj.bjc.6604749] [Cited by in Crossref: 71] [Cited by in F6Publishing: 82] [Article Influence: 5.1] [Reference Citation Analysis]
46 Senesse P, Assenat E, Schneider S, Chargari C, Magné N, Azria D, Hébuterne X. Nutritional support during oncologic treatment of patients with gastrointestinal cancer: Who could benefit? Cancer Treatment Reviews 2008;34:568-75. [DOI: 10.1016/j.ctrv.2008.03.003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
47 Chiarion-sileni V, Innocente R, Cavina R, Ruol A, Corti L, Pigozzo J, Del Bianco P, Fumagalli U, Santoro A, Ancona E. Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. Cancer Chemother Pharmacol 2009;63:1111-9. [DOI: 10.1007/s00280-008-0834-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
48 Tougeron D, Di Fiore F, Hamidou H, Rigal O, Paillot B, Michel P. Response to definitive chemoradiotherapy and survival in patients with an oesophageal adenocarcinoma versus squamous cell carcinoma: a matched-pair analysis. Oncology 2007;73:328-34. [PMID: 18497505 DOI: 10.1159/000134476] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
49 Kogo M, Suzuki A, Kaneko K, Yoneyama K, Imawari M, Kiuchi Y. Scoring system for predicting response to chemoradiotherapy, including 5-Fluorouracil and platinum, for patients with esophageal cancer. Dig Dis Sci 2008;53:2415-21. [PMID: 18256935 DOI: 10.1007/s10620-007-0149-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
50 Craig C, Gray J, Macpherson M, Hodgson H, Zammit M, Fullarton G. Porfimer sodium photodynamic therapy in the treatment of early oesophageal carcinoma. Photodiagnosis and Photodynamic Therapy 2007;4:244-8. [DOI: 10.1016/j.pdpdt.2007.09.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
51 Rades D, Golke H, Schild SE, Kilic E. The impact of tumor expression of erythropoietin receptors and erythropoietin on clinical outcome of esophageal cancer patients treated with chemoradiation. Int J Radiat Oncol Biol Phys 2008;71:152-9. [PMID: 17967510 DOI: 10.1016/j.ijrobp.2007.09.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
52 Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Kim WK, Lee JS, Kang YK. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Jpn J Clin Oncol. 2007;37:30-37. [PMID: 17272321 DOI: 10.1093/jjco/hyl134] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
53 Crumley AB, Stuart RC, McKernan M, McDonald AC, McMillan DC. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer. J Gastroenterol Hepatol 2008;23:e325-9. [PMID: 17645468 DOI: 10.1111/j.1440-1746.2007.05105.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
54 Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Critical Reviews in Oncology/Hematology 2007;63:12-31. [DOI: 10.1016/j.critrevonc.2007.02.001] [Cited by in Crossref: 410] [Cited by in F6Publishing: 382] [Article Influence: 27.3] [Reference Citation Analysis]
55 Jones RJ, Hawkins RE, Eatock MM, Ferry DR, Eskens FALM, Wilke H, Evans TRJ. A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol 2008;61:435-41. [DOI: 10.1007/s00280-007-0486-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 3.5] [Reference Citation Analysis]
56 van Meerten E, Eskens FA, van Gameren EC, Doorn L, van der Gaast A. First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer 2007;96:1348-52. [PMID: 17437008 DOI: 10.1038/sj.bjc.6603750] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
57 Chiarion-Sileni V, Corti L, Ruol A, Innocente R, Boso C, Del Bianco P, Pigozzo J, Mazzarotto R, Tomassi O, Ancona E. Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer 2007;96:432-8. [PMID: 17245338 DOI: 10.1038/sj.bjc.6603585] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
58 Homs MY, v.d. Gaast A, Siersema PD, Steyerberg EW, Kuipers EJ, Kuipers EJ. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd004063.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
59 Steyerberg EW, Neville BA, Koppert LB, Lemmens VE, Tilanus HW, Coebergh JW, Weeks JC, Earle CC. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 2006;24:4277-84. [PMID: 16963730 DOI: 10.1200/JCO.2005.05.0658] [Cited by in Crossref: 170] [Cited by in F6Publishing: 47] [Article Influence: 10.6] [Reference Citation Analysis]
60 Lagarde SM, ten Kate FJ, Reitsma JB, Busch OR, van Lanschot JJ. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 2006;24:4347-4355. [PMID: 16963732 DOI: 10.1200/jco.2005.04.9445] [Cited by in Crossref: 91] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
61 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]
62 Di Fiore F, Lecleire S, Galais M, Rigal O, Vié B, David I, Hamidou H, Paillot B, Jacob J, Michel P. Impact of radiation schedule and chemotherapy duration in definitive chemoradiotherapy regimen for esophageal cancer. Gastroentérologie Clinique et Biologique 2006;30:845-51. [DOI: 10.1016/s0399-8320(06)73331-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
63 Rades D, Tribius S, Yekebas EF, Bahrehmand R, Wildfang I, Kilic E, Muellerleile U, Gross E, Schild SE, Alberti W. Epoetin alfa improves survival after chemoradiation for Stage III esophageal cancer: Final results of a prospective observational study. International Journal of Radiation Oncology*Biology*Physics 2006;65:459-65. [DOI: 10.1016/j.ijrobp.2005.12.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
64 Rades D, Lang S, Schild S, Alberti W. Prognostic Value of Haemoglobin Levels During Concurrent Radio-chemotherapy in the Treatment of Oesophageal Cancer. Clinical Oncology 2006;18:139-44. [DOI: 10.1016/j.clon.2005.10.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
65 Trumper M, Ross PJ, Cunningham D, Norman AR, Hawkins R, Seymour M, Harper P, Iveson T, Nicolson M, Hickish T. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. Eur J Cancer. 2006;42:827-834. [PMID: 16466913 DOI: 10.1016/j.ejca.2005.08.044] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 4.0] [Reference Citation Analysis]
66 Steyerberg EW, Homs MY, Stokvis A, Essink-bot M, Siersema PD. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. Gastrointestinal Endoscopy 2005;62:333-40. [DOI: 10.1016/s0016-5107(05)01587-7] [Cited by in Crossref: 69] [Cited by in F6Publishing: 12] [Article Influence: 4.1] [Reference Citation Analysis]
67 Toh CK, Heng D, Ong YK, Leong SS, Wee J, Tan EH. Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma. Br J Cancer 2005;92:1382-7. [PMID: 15812546 DOI: 10.1038/sj.bjc.6602525] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
68 Rades D, Schild SE, Bahrehmand R, Zschenker O, Alberti WA, Rudat VR. Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy: the importance of pretreatment hemoglobin levels. Cancer 2005;103:1740-6. [PMID: 15742330 DOI: 10.1002/cncr.20952] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
69 Meerten EV, van der Gaast A. Systemic treatment for oesophageal cancer. European Journal of Cancer 2005;41:664-72. [DOI: 10.1016/j.ejca.2004.10.030] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
70 Scheithauer W. Esophageal cancer: chemotherapy as palliative therapy. Ann Oncol. 2004;15 Suppl 4:iv97-i100. [PMID: 15477344 DOI: 10.1093/annonc/mdh911] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
71 Saletti P, Ghielmini M, Martinoli S, Goldhirsch A. Sustained complete remission of metastatic oesophageal adenocarcinoma using long-term therapy with 5-fluorouracil. Annals of Oncology 2004;15:1145-6. [DOI: 10.1093/annonc/mdh269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
72 Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-403. [PMID: 15197201 DOI: 10.1200/JCO.2004.08.154] [Cited by in Crossref: 322] [Cited by in F6Publishing: 159] [Article Influence: 17.9] [Reference Citation Analysis]